表皮生长因子受体表达与结直肠癌患者化疗耐药及预后的关系

目的研究表皮生长因子受体（epidermal growth factor receptor，EGFR）与结直肠癌（colorectal cancer，CRC）患者化疗耐药及预后的关系。 方法采用免疫组化法分析2010年4月至2012年9月寿光市人民医院37名CRC患者肿瘤组织中EGFR表达强度，采用复合评分系统（0~9）进行评价，并分析其与不同临床病理特征及化疗耐药之间的关系。 结果高分化、中分化、低分化CRC肿瘤组织及正常结直肠组织EGFR表达阳性率分别为25%、56.25%、84.62%和16.67%。低分化、中分化CRC患者EGFR阳性表达率与高分化CRC和正常直肠组织相比，差异有统计学意义（χ²=8.576，P=0.003）。37名患者中EGFR强表达率为67.57%。EGFR强表达与CRC临床分期（χ²=4.68，P=0.030）及化疗反应率（χ²=7.27，P=0.007）显著相关。 结论EGFR强表达（复合评分≥6）预示化疗反应率低，可能成为CRC化疗耐药的预测指标。

Impact of EGFR expression on chemoresistance and prognosis of colorectal cancer patients

ObjectiveTo investigate the impact of EGFR expression on chemoresistance and prognosis of colorectal cancer. MethodsEGFR expression was analyzed by immunohistochemistry, CRC tumor tissues were collected from 37 patients of People′s Hospital of Shouguang. A complex score (0~9) was used to evaluated the EGFR immunohistochemical reactivity. Relationship among EGFR strong expression (score≥6), clinico-histological features and chemotherapy response rate were analyses. ResultsEGFR positive rates in high, middle, low differentiation CRC specimens and normal rectal tissues were 25%, 56.25%, 84.62% and 16.67%, respectively. EGFR positive rates in middle and low differentiation CRC specimens were significant higher than that in the high differentiation ones and normal rectal tissues (χ²=8.576, P=0.003). EGFR was high expressed in 37 patient (67.57%). Both CRC clinical stage (χ²=4.68, P=0.030) and chemotherapy response rate (χ²=7.27, P=0.007) showed significant correlation with EGFR expression. ConclusionsEGFR expression levels in CRC tumor tissues may be used to predict the chemoresistance of CRC.